These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 35106617)

  • 1. Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial.
    Hagel S; Bach F; Brenner T; Bracht H; Brinkmann A; Annecke T; Hohn A; Weigand M; Michels G; Kluge S; Nierhaus A; Jarczak D; König C; Weismann D; Frey O; Witzke D; Müller C; Bauer M; Kiehntopf M; Neugebauer S; Lehmann T; Roberts JA; Pletz MW;
    Intensive Care Med; 2022 Mar; 48(3):311-321. PubMed ID: 35106617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial.
    Hagel S; Fiedler S; Hohn A; Brinkmann A; Frey OR; Hoyer H; Schlattmann P; Kiehntopf M; Roberts JA; Pletz MW;
    Trials; 2019 Jun; 20(1):330. PubMed ID: 31171029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
    Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
    Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP.
    Gatti M; Rinaldi M; Tonetti T; Siniscalchi A; Viale P; Pea F
    Antibiotics (Basel); 2024 Mar; 13(4):. PubMed ID: 38666972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Balancing the scales: achieving the optimal beta-lactam to beta-lactamase inhibitor ratio with continuous infusion piperacillin/tazobactam against extended spectrum beta-lactamase producing
    Cojutti PG; Pai MP; Tonetti T; Siniscalchi A; Viale P; Pea F
    Antimicrob Agents Chemother; 2024 Apr; 68(4):e0140423. PubMed ID: 38411995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients.
    Schoenenberger-Arnaiz JA; Ahmad-Diaz F; Miralbes-Torner M; Aragones-Eroles A; Cano-Marron M; Palomar-Martinez M
    Eur J Hosp Pharm; 2020 Mar; 27(e1):e30-e35. PubMed ID: 32296502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.
    Taccone FS; Laterre PF; Dugernier T; Spapen H; Delattre I; Wittebole X; De Backer D; Layeux B; Wallemacq P; Vincent JL; Jacobs F
    Crit Care; 2010; 14(4):R126. PubMed ID: 20594297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Piperacillin-Tazobactam Compared With Cefoxitin as Antimicrobial Prophylaxis for Pancreatoduodenectomy: A Randomized Clinical Trial.
    D'Angelica MI; Ellis RJ; Liu JB; Brajcich BC; Gönen M; Thompson VM; Cohen ME; Seo SK; Zabor EC; Babicky ML; Bentrem DJ; Behrman SW; Bertens KA; Celinski SA; Chan CHF; Dillhoff M; Dixon MEB; Fernandez-Del Castillo C; Gholami S; House MG; Karanicolas PJ; Lavu H; Maithel SK; McAuliffe JC; Ott MJ; Reames BN; Sanford DE; Sarpel U; Scaife CL; Serrano PE; Smith T; Snyder RA; Talamonti MS; Weber SM; Yopp AC; Pitt HA; Ko CY
    JAMA; 2023 May; 329(18):1579-1588. PubMed ID: 37078771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concerns about study design and suggestion of additional analysis of therapeutic drug monitoring-guided piperacillin/tazobactam therapy for patients with sepsis.
    Yoshihiro S; Taito S
    Intensive Care Med; 2022 Jun; 48(6):770-771. PubMed ID: 35182165
    [No Abstract]   [Full Text] [Related]  

  • 10. Case-control study of drug monitoring of β-lactams in obese critically ill patients.
    Hites M; Taccone FS; Wolff F; Cotton F; Beumier M; De Backer D; Roisin S; Lorent S; Surin R; Seyler L; Vincent JL; Jacobs F
    Antimicrob Agents Chemother; 2013 Feb; 57(2):708-15. PubMed ID: 23147743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concerns about study design and suggestion of additional analysis of therapeutic drug monitoring-guided piperacillin/tazobactam therapy for patients with sepsis. Author's reply.
    Hagel S; Pletz MW; Lehmann T
    Intensive Care Med; 2022 Jun; 48(6):772-773. PubMed ID: 35292826
    [No Abstract]   [Full Text] [Related]  

  • 12. Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach for Maximizing the Effectiveness of Monotherapy Even in the Treatment of Critically Ill Patients with Documented Extended-Spectrum Beta-Lactamase-Producing
    Gatti M; Rinaldi M; Tonetti T; Siniscalchi A; Viale P; Pea F
    Antibiotics (Basel); 2023 Dec; 12(12):. PubMed ID: 38136770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study.
    Réa-Neto A; Niederman M; Lobo SM; Schroeder E; Lee M; Kaniga K; Ketter N; Prokocimer P; Friedland I
    Curr Med Res Opin; 2008 Jul; 24(7):2113-26. PubMed ID: 18549664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher than standard dosing regimen are needed to achieve optimal antibiotic exposure in critically ill patients with augmented renal clearance receiving piperacillin-tazobactam administered by continuous infusion.
    Carrié C; Legeron R; Petit L; Ollivier J; Cottenceau V; d'Houdain N; Boyer P; Lafitte M; Xuereb F; Sztark F; Breilh D; Biais M
    J Crit Care; 2018 Dec; 48():66-71. PubMed ID: 30172963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients.
    Dhaese SAM; Roberts JA; Carlier M; Verstraete AG; Stove V; De Waele JJ
    Int J Antimicrob Agents; 2018 Apr; 51(4):594-600. PubMed ID: 29277531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-Time TDM-Guided Optimal Joint PK/PD Target Attainment of Continuous Infusion Piperacillin-Tazobactam Monotherapy Is an Effective Carbapenem-Sparing Strategy for Treating Non-Severe ESBL-Producing
    Gatti M; Bonazzetti C; Pascale R; Giannella M; Viale P; Pea F
    Microorganisms; 2024 Jan; 12(1):. PubMed ID: 38257978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality of Patients With Sepsis Administered Piperacillin-Tazobactam vs Cefepime.
    Chanderraj R; Admon AJ; He Y; Nuppnau M; Albin OR; Prescott HC; Dickson RP; Sjoding MW
    JAMA Intern Med; 2024 Jul; 184(7):769-777. PubMed ID: 38739397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
    Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
    Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
    Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing.
    Burgess DS; Waldrep T
    Clin Ther; 2002 Jul; 24(7):1090-104. PubMed ID: 12182254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.